Diamant Thaçi, EADV 2020 – Long-term Efficacy of Tildrakizumab in Psoriasis
It was an honour to talk with Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754). Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled ‘Long-term […]
